000			03976nam a22005417a 4500
008			170411s20162016 xxu||||| |||| 00| 0 eng d
022			_a0002-8703
040			_aOvid MEDLINE(R)
099			_a27297851
245			_aA randomized controlled trial of levosimendan to reduce mortality in high-risk cardiac surgery patients (CHEETAH): Rationale and design.
251			_aAmerican Heart Journal. 177:66-73, 2016 Jul
252			_aAm Heart J. 177:66-73, 2016 Jul
253			_aAmerican heart journal
260			_c2016
260			_fFY2017
266			_d2017-05-24
501			_aAvailable online from MWHC library: 1995 - present, Available in print through MWHC library: 1999 - 2006
520			_aCONCLUSIONS: This trial is planned to determine whether levosimendan could improve survival in patients with postoperative low cardiac output syndrome. The results of this double-blind, placebo-controlled randomized trial may provide important insights into the management of low cardiac output in cardiac surgery.
520			_aCopyright � 2016 Elsevier Inc. All rights reserved.
520			_aDESIGN: Double-blind, placebo-controlled, multicenter randomized trial.
520			_aINTERVENTIONS: Cardiac surgery patients (n = 1,000) with postoperative myocardial dysfunction (defined as patients with intraaortic balloon pump and/or high-dose standard inotropic support) will be randomized to receive a continuous infusion of either levosimendan (0.05-0.2 mug/[kg min]) or placebo for 24-48 hours.
520			_aMEASUREMENTS AND MAIN RESULTS: The primary end point will be 30-day mortality. Secondary end points will be mortality at 1 year, time on mechanical ventilation, acute kidney injury, decision to stop the study drug due to adverse events or to start open-label levosimendan, and length of intensive care unit and hospital stay. We will test the hypothesis that levosimendan reduces 30-day mortality in cardiac surgery patients with postoperative myocardial dysfunction.
520			_aOBJECTIVE: Patients undergoing cardiac surgery are at risk of perioperative low cardiac output syndrome due to postoperative myocardial dysfunction. Myocardial dysfunction in patients undergoing cardiac surgery is a potential indication for the use of levosimendan, a calcium sensitizer with 3 beneficial cardiovascular effects (inotropic, vasodilatory, and anti-inflammatory), which appears effective in improving clinically relevant outcomes.
520			_aSETTING: Tertiary care hospitals.
546			_aEnglish
650			_a*Cardiac Output, Low/th [Therapy]
650			_a*Cardiotonic Agents/tu [Therapeutic Use]
650			_a*Hydrazones/tu [Therapeutic Use]
650			_a*Intra-Aortic Balloon Pumping
650			_a*Postoperative Complications/th [Therapy]
650			_a*Pyridazines/tu [Therapeutic Use]
650			_aAcute Kidney Injury/ep [Epidemiology]
650			_aCardiac Output, Low/mo [Mortality]
650			_aCardiac Surgical Procedures/mo [Mortality]
650			_aDouble-Blind Method
650			_aHumans
650			_aInfusions, Intravenous
650			_aIntensive Care Units
650			_aLength of Stay/sn [Statistics & Numerical Data]
650			_aPostoperative Complications/mo [Mortality]
650			_aRespiration, Artificial
651			_aMedStar Heart & Vascular Institute
657			_aJournal Article
700			_aLipinski, Michael J
790			_aAlvaro G, Amantea B, Auci E, Auriemma S, Baiocchi M, Bianchi A, Biondi-Zoccai G, Bove T, Bradic N, Buscaglia G, Calabro MG, Cariello C, Corcione A, De Vuono G, Fominskiy E, Frontini M, Galdieri N, Gemma M, Gianni S, Grigoryev E, Guarracino F, Landoni G, Lembo R, Likhvantsev V, Lipinski MJ, Lobreglio R, Lomivorotov VV, Monaco F, Pala G, Paternoster G, Pisano A, Sangalli F, Wang CY, Zangrillo A, Zucchetti MC
856			_uhttps://dx.doi.org/10.1016/j.ahj.2016.03.021 _zhttps://dx.doi.org/10.1016/j.ahj.2016.03.021
942			_cART _dArticle
999			_c2410 _d2410